B-RAF with PLX4032: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 13: | Line 13: | ||
<scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene><br> | <scene name='B-RAF_with_PLX4032/Phe_595_dfg_out/1'>DFG out</scene><br> | ||
<scene name='B-RAF_with_PLX4032/Superposition3og71uwh/1'>Superposition</scene> | <scene name='B-RAF_with_PLX4032/Superposition3og71uwh/1'>Superposition</scene> | ||
<applet load='3og7' size=' | <applet load='3og7' size='700' color='white' frame='true' align='center' caption='testcaption' /> | ||
Revision as of 19:06, 5 October 2010
B-RAF with PLX4032
PLX4032 is a newly synthesized drug that is being used to treat malignant melanoma with a specific mutation. The mutation is B-RAF^(V600E). This drug is highly selective for this mutation and will not bind to wild type B-RAF.
PLX 4032
ATP
Wild-Type B-RAF
V600E Mutation
PLX4032 Sulfonamide N
H-Bond Interaction Asp594 and PLX4032
DFG in
DFG out
Superposition
|
